# Advances in immunotherapy for thyroid malignancies: from molecular targets to clinical outcomes

## TL;DR

This paper reviews recent advances in immunotherapy for thyroid cancers, focusing on new treatments and their potential to improve outcomes for difficult-to-treat cases.

## Contribution

The paper provides a comprehensive overview of novel immunotherapeutic strategies and their translational potential for thyroid malignancies.

## Key findings

- Immune checkpoint inhibitors show efficacy in anaplastic and medullary thyroid cancers.
- Next-generation immune modulators and vaccines targeting specific mutations are being tested.
- Combining immunotherapy with other treatments enhances anti-tumor effects.

## Abstract

Thyroid cancers comprise a diverse collection of endocrine tumors, notably papillary, follicular, medullary, and anaplastic carcinomas, each differentiated by their molecular alterations, clinical behavior, and responsiveness to therapies. Current treatment algorithms of surgical resection, radioiodine treatment, and selective small-molecule inhibitors, although effective for many cases, confront significant limitations, particularly in anaplastic and advanced medullary tumors, where resistance to conventional agents correlates with diminished prognosis, thereby demanding the exploration of innovative therapeutic strategies.

This article reviews contemporary immunotherapy-directed interventions for thyroid cancers, highlighting the elucidation of actionable tumor antigens, the reengineering of the immunologic tumor microenvironment, and the ongoing efforts to translate these laboratory findings into practicable, evidence-based clinical protocols.

Recent studies underscore the critical efficacy of immune checkpoint inhibitors targeting the PD-1/PD-L1 and CTLA-4 pathways in select populations of anaplastic thyroid carcinoma (ATC), medullary thyroid carcinoma (MTC), and PD-L1-expressing differentiated thyroid cancers. Next-generation immune modulators, specifically inhibitors directed against LAG-3 and TIM-3, are being evaluated in combinatorial frameworks. Vaccines engineered to elicit responses against the BRAFV600E mutation, RET/PTC fusions, and additional neoantigens have shown promising immunogenic profiles in preliminary trial cohorts, while adoptive transfer methodologies, including tumor-infiltrating lymphocyte (TIL) mobilization and engineered CAR-T lymphocytes, are progressing through preclinical and early-phase clinical benchmarks. Concurrently, oncolytic viral vectors are being harnessed to amplify neoantigen liberation and, consequently, to amplify systemic immunity. When immunotherapeutic modalities are judiciously aligned with tyrosine kinase inhibitors (TKIs) or radiotherapeutic regimens, cumulative anti-tumor effects are accentuated, purportedly through mechanisms such as immunogenic cell death induction and the reprograming of immune-tolerant tumor ecosystems.

Immunotherapy is set to transform the treatment paradigm for thyroid cancers, although remaining hurdles, the disquietingly low baseline immunogenicity of differentiated tumors, the rapid, capricious emergence of resistance, and complex immune-related endocrine toxicities, must be systematically addressed. Success in this arena will hinge on utilitarian biomarker-based cohort selection, the discovery of fresh immunogenic epitopes, and the meticulous design of synergistic treatment combinations. The synergistic leverage of genomic, transcriptomic, and immune landscape dissection, coupled with cutting-edge engineered lymphocyte platforms and engineered oncolytic vectors, may finally position immunotherapy as an unassailable pillar of bespoke medicine for advanced thyroid carcinomas.